Tislelizumab（neoadjuvant）
SYSKY-2022-256-1
Phase 3 small_molecule active
Quick answer
Tislelizumab（neoadjuvant） for Head and Neck Squamous Cell Carcinomas is a Phase 3 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Head and Neck Squamous Cell Carcinomas
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active